The use of metformin in standard cancer therapy may improve both overall and cancer-specific survival of patients with diabetes and breast cancer.
Addition of single-dose fosaprepitant was well tolerated and demonstrated superior control of chemotherapy-induced nausea and vomiting (CINV).
Addition of transarterial chemoembolization to sorafenib for treatment of hepatocellular carcinoma (HCC) displayed no survival advantage.
Mutations in BRCA2 account for more than 50% of patients with pancreatic adenocarcinoma with an identified susceptibility syndrome.
The FDA has approved expanded indication for the Optune device to treat patients with newly diagnosed glioblastoma multiforme.
Administration of intravenous immune globulin (IVIg) to prevent infection may contribute to the risk of thromboembolic events.
BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history.
Olaparib plus paclitaxel is active in the treatment of patients with metastatic gastric cancer.
Modified docetaxel, cisplatin, and fluorouracil (mDCF) is less toxic than DCF, even when supported with granulocyte colony-stimulating factor (GCSF).
Routine imaging in patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) is not recommended.
Newly identified prognostic markers may accurately stratify for survival in mycosis fundoides (MF) and Sézary syndrome (SS).
Treatment with anti-EGFR monoclonal antiboday (MoAb) should only be considered in metastatic colorectal cancer (mCRC) without RAS mutations.
Genome-wide association-studies (GWAS) can be used to establish allele mismatch in acute-graft-versus-host disease (aGVHD).
Preoperative proteinuria is a significant predictor of overall survival in patients with renal cancer undergoing partial or radical nephrectomy.
Training of patients with melanoma and partners in early detection skin self-examinations benefited those patients with low relationship quality.
A new staging system for intrahepatic cholangiocarcinoma (ICC) may be more effective in determining which patients to assign to surgery.
Prostate cancer patients on active surveillance who experienced volume re-classification at substantially higher risk of developing grade re-classification.
The FDA has granted accelerated approval for pembrolizumab (Keytruda) for treatment of advanced (metastatic) non-small cell lung cancer (NSCLC).
Gonadotropin-releasing hormone (GnRH) agonists administered with chemotherapy was associated with increased rates of recovery of regular menses.
Most US women undergoing BRCA genetic testing do not receive genetic counseling despite multiple guidelines.
Sign Up for Free e-newsletters
Breast Cancer Awareness Month Poll
Cancer Therapy Advisor Articles
- FDA Approves Pembrolizumab for Metastatic Non-Small Cell Lung Cancer
- Prostate Cancer Q&A With Key Opinion Leader David F. Penson, MD
- Viral MicroRNA Expression Linked to Worse Clinical Outcomes in Early Stage Malignancies
- Neutrophil, Lymphocyte Ratio May Predict Survival in Head and Neck Cancer
- Higher Than Expected "Real-World" Hospitalizations Associated With Systemic Cancer Therapy
- For Node-Positive Breast Cancer, EC-T Remains Standard Adjuvant Regimen
- Metformin Use May Improve Survival in Patients With Breast Cancer, Diabetes
- Adding Single-Dose Fosaprepitant Improves CINV Control
- No Survival Advantage Displayed With Transarterial Chemoembolization
- Upper Gastrointestinal Bleeding Secondary to Malignancy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|